FDA Approved Products
6,646 products with lifecycle intelligence, competitive pressure scores, and patent timelines.
AVODART
dutasteride
LOE Approaching
Viatris (2)
ORAL · CAPSULE
symptomatic benign prostatic hyperplasia (BPH) in men with an enlarged prostate to: () • improve symptoms• reduce the risk of acute urinary retention+5
2001
NDA30/100
AVOPEF
etoposide
Launch
Viatris (2)
INTRAVENOUS · INJECTABLE
refractory testicular cancer in adult patientslung cancer
2026
NDA30/100
AXERT
almotriptan malate
LOE Approaching
Johnson & Johnson
ORAL · TABLET
cluster headache () 1migraine+1
2001
NDA30/100
AXID
nizatidine
LOE Approaching
GSK
ORAL · CAPSULE
1988
NDA30/100
AXID
nizatidine
LOE Approaching
ORAL · SOLUTION
2004
NDA30/100
AXID AR
nizatidine
LOE Approaching
GSK
ORAL · TABLET
1996
NDA30/100
AXTLE
pemetrexed
Growth
Viatris (2)
INTRAVENOUS · POWDER
non-small cell lung cancerlung cancer
2024
NDA30/100
AYGESTIN
norethindrone acetate
LOE Approaching
ORAL · TABLET
pregnancy in women
1982
NDA30/100
AZACITIDINE
azacitidine
Peak
Teva
INTRAVENOUS, SUBCUTANEOUS · POWDER
refractory anemia with ringed sideroblasts (if accompanied by neutropeniathrombocytopenia+6
2016
NDA30/100
AZACTAM
aztreonam
LOE Approaching
Bristol Myers Squibb
INJECTION · INJECTABLE
the following infections caused by susceptible Gram-negative microorganisms: Urinary Tract Infections (complicateduncomplicated)+10
1986
NDA30/100
AZACTAM IN PLASTIC CONTAINER
aztreonam
LOE Approaching
Bristol Myers Squibb
INJECTION · INJECTABLE
the following infections caused by susceptible Gram-negative microorganisms: Urinary Tract Infections (complicateduncomplicated)+10
1989
NDA30/100
AZASITE
azithromycin monohydrate
LOE Approaching
Thea Pharma
OPHTHALMIC · SOLUTION/DROPS
bacterial conjunctivitis caused by susceptible isolates of the following microorganisms: CDC coryneform group GHaemophilus influenzae+3
2007
NDA30/100
AZEDRA
iobenguane i-131
Peak
Progenicyte Therapeutics
INTRAVENOUS · SOLUTION
2018
NDA30/100
AZELEX
azelaic acid
LOE Approaching
Almirall
TOPICAL · CREAM
1995
NDA30/100
AZITHROMYCIN
azithromycin
LOE Approaching
Entera Bio
INJECTION · INJECTABLE
development of drug-resistant bacteriamaintain the effectiveness of azithromycin for oral suspension+5
2006
NDA30/100
AZMACORT
triamcinolone acetonide
LOE Approaching
AbbVie
INHALATION · AEROSOL, METERED
1982
NDA30/100
AZO GANTRISIN
phenazopyridine hydrochloride; sulfisoxazole
LOE Approaching
Roche
ORAL · TABLET
paindiscomfort during the interval before antimicrobial therapy controls the infection
1990
SMNDA30/100
AZOPT
brinzolamide
LOE Approaching
Novartis
OPHTHALMIC · SUSPENSION/DROPS
elevated intraocular pressure (IOP) in patients with ocular hypertensionopen-angle glaucoma+3
1998
NDA30/100
AZOR
amlodipine besylate and olmesartan medoxomil
LOE Approaching
ORAL · TABLET
hypertensionalone+3
2007
NDA30/100
AZULFIDINE
sulfasalazine
LOE Approaching
Pfizer
ORAL · TABLET
ulcerative colitiswhom there is evidence+2
1950
NDA30/100
AZULFIDINE
sulfasalazine
LOE Approaching
Pfizer
ORAL · SUSPENSION
ulcerative colitiswhom there is evidence+2
1980
NDA30/100
AZULFIDINE
sulfasalazine
LOE Approaching
Pfizer
ORAL · TABLET
ulcerative colitiswhom there is evidence+2
1996
NDA30/100
AZULFIDINE EN-TABS
sulfasalazine
LOE Approaching
Pfizer
ORAL · TABLET
ulcerative colitiswhom there is evidence+2
2000
NDA30/100
AZULFIDINE EN-TABS
sulfasalazine
LOE Approaching
Pfizer
ORAL · TABLET, DELAYED RELEASE
ulcerative colitiswhom there is evidence+2
1950
NDA30/100